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The most elusive period in Plasmodium’s 
life cycle spans from the moment a human 
feels the sting of an infected mosquito to 
the time the victim starts to shiver—a sign 
that the parasite has infected the red blood 
cells. During this interval, the bugs are 
few in number, and they dash to the liver 
at high speeds.
At the Pasteur Institute in Paris, 
Robert Ménard spies on the parasites’ 
journey in real-time to figure out how 
they move and gain access to their various 
cellular targets. How pathogens sneak 
into cells is a question 
that has interested Ménard 
since the start of his re-
search career. As a Ph.D. 
student, he identified the 
proteins that Shigella, the 
bacterium that causes 
dysentery, uses to pene-
trate the gut epithelium 
(1, 2). Later, as a post-
doctoral fellow, Ménard discovered 
that  Plasmodium uses a protein called 
circumsporozoite to both develop inside 
the mosquito midgut and to grab on to 
mammalian liver cells (3).
After starting his own lab in 2001, 
Ménard developed techniques to track 
Plasmodium during its odyssey within 
infected mosquitoes and mice. His dis-
coveries have challenged many pre-
sumptions about Plasmodium’s early 
behavior within the host.
Ménard’s movies show that in-
jected parasites don’t just glide to the 
liver as previously thought. Some 
make a detour to lymph nodes—one 
of the training centers of the immune 
system (4), while others remain at the 
bite site (5). Those that make it to the 
liver shield themselves from macro-
phages and dendritic cells by clustering 
within vacuole-like structures called 
merosomes that eventually bud out 
into the blood (6). Ménard is now 
combining genetic tools with his 
movie-making skills to identify host 
and parasite genes that direct the para-
sites’ early itinerary within the host.
MOVING INTO MALARIA
Did you grow up wanting to make 
movies on disease-causing bugs?
No, I actually wanted to be a doctor and 
initially went to medical school to study 
neurology. But then I went to Asia for 
two years in the middle of my medical 
studies to get some fi  eld experience. I 
spent some time working in rural clinics 
near Pune in India and in a small biology 
lab in Jakarta, and somewhere along the 
way, I guess I got bitten by the infectious 
disease bug.
Not literally, I hope. What happened after 
you got back to France?
Unfortunately, in France it’s diffi   cult to 
do both medical studies and research at 
the same time, because we don’t have the 
same sort of M.D./Ph.D. programs that 
you have in the US. After I fi  nished the 
M.D. part, I wanted to switch to research, 
but the problem was that I was no scien-
tist. So I ended up as a graduate student 
in Phillipe Sansonetti’s lab at the Pasteur 
and worked on bacterial dysentery, an 
infectious disease problem worldwide.
How did your interest in malaria come 
about?
It defi   nitely wasn’t a predetermined 
choice but has more to do with the 
chaotic nature of life (mine, at least). I 
wanted to move to New York for per-
sonal reasons. Victor Nussenzweig’s lab at 
New York University and his work on 
malaria was especially attractive for post-
doctoral work because I thought malaria 
was a wonderful opening into the world 
of parasitology. And although I wouldn’t 
be in that world as a medical doctor, I 
could still contribute my research expertise 
to an important global health problem.
MUTATING PARASITES
How did your work in the Nussenzweig 
lab contribute to the fi  eld?
I got to Victor’s lab just when there was a 
major technical breakthrough in the fi  eld. 
Others had fi  gured out how to stably 
transfect malaria parasites and integrate 
modifi  ed genes into the parasites’ genome. 
I used this technology to create the 
first mutant Plasmodium that lacked 
the circumsporozoite protein, which is 
the major protein in the sporozoite—the 
parasitic form that’s transmitted by 
the mosquito.
Why focus on this protein?
The entire fi  eld was interested in this 
protein as a vaccine target because it is 
essential for the parasite’s infectivity in 
mammals and is expressed at a stage 
when the parasite has not yet infected 
the red blood cell. So stopping the para-
site at this stage of the infection might 
potentially prevent the triggering of the 
disease. Because this protein covered the 
sporozoite surface, we expected to get 
a mutant sporozoite that lacked this 
protein. But what we got instead was a 
parasite that could not form sporozoites 
at all. That fi  nding led to us showing that 
this protein was also required for the 
parasite’s development in the mosquito.
And what did you learn about the 
parasite’s motility?
We did in vitro work looking at sporo-
zoites slithering around on glass slides to 
study their motility. Using gene target-
ing, we found that the parasite relies on 
a transmembrane protein called TRAP 
to move with its characteristic gliding 
motion—a form of locomotion where 
Robert Ménard is stalking the malaria parasite Plasmodium from the moment 
it invades the skin to find a way to stop its infection cycle.
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there’s no change in cell shape. But we 
didn’t know anything about sporozoite 
motility inside the mammalian host.
REAL-TIME SURVEILLANCE
And you moved back to Paris to pursue 
this question?
When my postdoc ended, it was the 
perfect time for me to go back to the 
Pasteur, which to me is one of the tem-
ples of infectious disease research. At the 
time, the director, Philippe Kourilsky, 
was steering the institute toward giving 
more responsibility to young people and 
allowing them to head labs. I started 
putting together a project using time-lapse 
microscopy techniques and molecular 
and genetic approaches that I had learned 
in Victor’s lab to dissect the preerythro-
cytic stage of the parasite life cycle.
Until quite recently, this stage was 
believed to be very rapid and simple: 
the sporozites were thought to zip 
from the skin to the liver, differentiate 
and multiply inside the hepatocytes, 
and then escape into the blood. This 
was thought to be the starting point for 
all the action, as it was presumed that 
there was little host–pathogen interac-
tion during the parasites’ trip to the 
liver and that the bugs were invisible 
to the immune system.
But you’ve now shown that this phase is 
actually very complex.
We’ve observed that the sporozoites that 
enter the skin have many fates and the 
liver is only one of many potential desti-
nations. We’ve found that some of the 
sporozoites lose their motility, stay in 
the skin, and might diff  erentiate there. 
Their presence in the skin triggers a 
great deal of infl  ammation, but we don’t 
yet understand all the stages of this 
immune response.
Some of the bugs move as fast as 
they do in vitro—we’ve estimated that 
they move at two to four microns per 
second—and reach the lymphatic system 
and infect the draining lymph nodes. 
The lymph node parasites, however, 
don’t actually develop into the form that 
can infect erythrocytes.
How does the parasite get away with 
growing right under the immune system’s 
nose, so to speak?
We don’t yet know what the bugs are 
doing inside the lymph nodes. Some of 
them do interact with the immune cells 
and some get degraded within hours of 
the bite, suggesting that the immune system 
might be attacking them. But the other 
possibility is that the partially developed 
parasites are desensitizing the body to 
their presence and escaping destruction 
by inducing immune tolerance.
The parasites that complete their mat-
uration in the liver also have a way of 
leaving the infected cell unnoticed. They 
enter the liver blood vessels within mero-
somes, which have budded out of the 
hepatocytes. The parasites also manipulate 
host cell membranes by preventing the 
exposure of danger signals that would 
attract liver macrophages to the infected 
cells. I think it’s one of the most sophisti-
cated forms of immune evasion. It’s much 
more than just one pathogen gene product 
modifying a set of genes of the host cell. 
It’s a mechanism that directs a new fate 
for the host cell.
COUNTER-MEASURES
Do your fi  ndings have implications for 
malaria vaccine development?
Ruth Nussenzweig discovered decades 
ago that injecting irradiated sporozoites, 
which reach the liver but fail to multiply, 
induces an immune response that com-
pletely wipes out the bugs. This approach 
is not practical, as it would require pro-
ducing and maintaining doses of vaccines 
made of live parasites 
that can only be grown 
within mosquitoes. 
But it tells us that it is 
possible to arrest this 
phase of infection.
Our studies sug-
gest that there are 
several target sites for 
interfering with the 
parasite during this stage. We still need 
to figure out what the parasites in the 
lymph node and the skin are doing to 
the immune system—inducing protec-
tive immunity or tolerance. But if we 
find that they are priming the immune 
system, we might be able to direct all 
injected parasites to that site by geneti-
cally modifying them. To that end, we’re 
currently generating mutants that get 
stuck in the skin (7).
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Real-time tracking of sporozoites (green, 
top) inside blood vessels (purple) reveals 
a trajectory (bottom) marked by stops 
(crosses) and high speed moves (lines).
Sporozoites (green) crawl through a mosquito’s 
gut (red arrowhead) toward the salivary gland 
(white arrowhead).
“I thought 
malaria was a 
wonderful 
opening into 
the world of 
parasitology.”